Loading...
Assessment of Disease‐Related Therapeutic Protein Drug‐Drug Interaction for Etrolizumab in Patients With Moderately to Severely Active Ulcerative Colitis
The efficacy and safety of etrolizumab, a humanized IgG1 mAb, were evaluated in patients with ulcerative colitis (UC) in a phase 2 study (EUCALYPTUS). The current study assessed the risk of therapeutic protein drug‐drug interaction (TP‐DDI) of etrolizumab on CYP3A activity in patients with UC. Liter...
Na minha lista:
| Udgivet i: | J Clin Pharmacol |
|---|---|
| Main Authors: | , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
John Wiley and Sons Inc.
2016
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5066705/ https://ncbi.nlm.nih.gov/pubmed/26412221 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.649 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|